周期联合甲氨蝶呤、环磷酰胺治疗类风湿关节炎的临床疗效及疗效预测因素分析

Clinical Efficacy and Predictive Factors of Cycle Combined With Methotrexate and Cyclophosphamide in the Treatment of Rheumatoid Arthritis

目的探讨周期联合甲氨蝶呤、环磷酰胺治疗类风湿关节炎的临床疗效及疗效预测因素分析。方法选取我院收治的100例类风湿关节炎患者的临床资料,全部患者均给予甲氨蝶呤、环磷酰胺联合治疗,统计观察全部患者的临床治疗效果,收集全部患者治疗前年龄、性别、病史、病变关节严重程度以及各相关检查结果等一般资料,对患者的临床治疗效果进行预测性分析。结果治疗后91例患者临床症状较前明显好转,治疗有效率为91.0%。治疗后患者ESR、CRP等检查结果较前均有所降低。其中年龄>60岁的老年患者、病变关节数量>5处,治疗前压痛关节数>5处的部分患者治疗效果较差,年龄较大、病变关节数量、治疗前压痛关节数可作为目前临床上应用的治疗疗效预测因素。结论周期联合甲氨蝶呤、环磷酰胺治疗类风湿关节炎具有较高的临床有效性,临床好转率高。而且,年龄较大、病变关节数量、治疗前压痛关节数可作为目前临床上应用的类风湿关节炎疗效预测因素。

Objective To investigate the clinical effect and predictive factor analysis of cycle combined with methotrexate, cyclophosphamide in treating rheumatoid arthritis. Methods 100 cases with rheumatoid arthritis in our hospital were selected and given methotrexate, cyclophosphamide treatment. Observed the clinical effect of all patients and general data like age, gender, medical history, lesion severity of patients were selected. Analyzed the clinical effect of all patients. Results Clinical symptoms of 91 cases obviously improved, treatment efficiency was 91.0%. ESR, CRP of patients obviously lowered after treatment. The age of 60, lesion number〉5, TJC〉5 part patients had poor effect. Older, the number of lesions, the number of pre treatment of the joint can be used as the current clinical application of predictive factors. Conclusion Cycle combined with methotrexate and cyclophosphamide in the treatment of rheumatoid arthritis with high clinical efficacy, clinical improvement rate is high. Moreover, the age, the number of joint lesions, the number of tender joints before treatment can be used as the current clinical application of rheumatoid arthritis curative effect prediction factors.